Peringkat dalam Saham
#38911
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Kapitalisasi Pasar
$681.26K
Perubahan (1 hari)
-3.69%
Perubahan (1 tahun)
-95.30%
Perdagangan Valion Bio, Inc. (VBIO)
Harga VBIO dengan kapitalisasi pasar B
Kapitalisasi pasar dari Valion Bio, Inc.(VBIO)
Kapitalisasi Pasar: $681.26K
Per August 2026, Valion Bio, Inc. memiliki kapitalisasi pasar sebesar $681.26K. Ini menjadikan Valion Bio, Inc. sebagai perusahaan 38911th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Valion Bio, Inc. dari 2021 hingga 2026
VBIO dibandingkan dengan 5 teratas stocks paling populer
| Harga VBIO |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.470T
|
+802,852,590.36%
|
|
|
|
|
$4.467T
|
+655,704,326.80%
|
|
|
|
|
$4.174T
|
+612,688,789.01%
|
|
|
|
|
$3.700T
|
+543,120,204.32%
|
|
|
|
|
$2.854T
|
+418,978,030.97%
|
